{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2015"],"condition":["Neoplasm Metastasis","Melanoma","Solid Tumors"],"disease":["Neoplasm Metastasis","Melanoma","Solid Tumors"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2179977"],"location":["United States","Australia"],"study_start_month":["1"],"keyword":["Metastatic Solid Tumors","Maximum Tolerated Dose","Relapsed or refractory, BRAFV600 or RAS-mutated solid tumors","Thyroid carcinomas","Locally Advanced Tumors","Non -small cell lung cancer [NSCLC]","Pancreatic ductal Adenocarcinomas","Colorectal Carcinomas Papillary"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors","description":"The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be adequately tolerated with minimal side effects.","dates":{"creation":"2015-01-15"},"accession":"2179977","cross_references":{"ClinicalTrials___gov":["NCT02313012"]}}